Englumafusp alfa plus glofitamab in B cell non‑Hodgkin lymphoma: a phase 1 trial
BRAF/MEK inhibition provided a sustained 18‑month clinical response in BRAF V600E‑mutated histiocytic/dendritic cell sarcoma, although subsequent evolution to high‑grade B‑cell lymphoma occurred.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?
- Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
- Lymphoma Clinical Trials and Research
- Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial
- Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias